Thrombotic Microangiopathies, Including Hemolytic Uremic Syndrome

Comprehensive Clinical Nephrology: Fourth Edition

Volumn , Issue , 2010, Pages 344-355

  Ruggenenti, Piero ^a   Cravedi, Paolo ^b   Remuzzi, Giuseppe ^b  

^a Mario Negri Institute for Pharmacological Research ^*  (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862685254     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-05876-6.00028-9     Document Type: Chapter

References (40)

1. Ruggenenti P, Noris M, Remuzzi G Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001, 60:831-846.
2. Noris M, Remuzzi G Hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16:1035-1050.
3. Rizzoni G, Claris-Appiani A, Edefonti A Plasma infusion for hemolytic uremic syndrome in children: Results of a multicenter controlled trial. J Pediatr 1988, 112:284-290.
4. Loirat C, Sonsino E, Hinglais N, et al. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 1988, 2:279-285.
5. Dundas S, Murphy J, Soutar RL, et al. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999, 354:1327-1330.
6. Carter AO, Borczyk AA, Carlson JA, et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 1987, 317:1496-1500.
7. Remuzzi G, Galbusera M, Salvadori M, et al. Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney Int 1996, 49:282-286.
8. McGraw ME, Lendon M, Stevens RF, et al. Haemolytic uraemic syndrome and the Thomsen Friedenreich antigen. Pediatr Nephrol 1989, 3:135-139.
9. Furlan M, Robles R, Lammle B Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996, 87:4223-4234.
10. Lammle B, Kremer Hovinga J, Studt JD Thrombotic thrombocytopenic purpura. Hematol J 2004, 5:S6-S11.
11. Moake JL Thrombotic microangiopathies. N Engl J Med 2002, 347:589-600.
12. Bell WR, Braine HG, Ness PM, Kickler TS Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991, 325:398-403.
13. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991, 325:393-397.
14. Byrnes JJ, Moake JL, Klug P, Periman P Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990, 34:169-174.
15. Garvey B Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008, 141:149-169.
16. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcome in a prospective cohort of 142 patients. Blood 2003, 102:60-68.
17. Yomtovian R, Niklinski W, Silver B, et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: A case report and review of the literature. Br J Haematol 2004, 124:787-795.
18. Bresin E, Gastoldi S, Daina E, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 2009, 101:233-238.
19. Noris M, Ruggenenti P, Perna A, et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 1999, 10:281-293.
20. Stratton JD, Warwicker P Successful treatment of factor H-related haemolytic uraemic syndrome. Nephrol Dial Transplant 2002, 17:684-685.
21. Noris M, Brioschi S, Caprioli J, et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2004, 362:1542-1547.
22. Alper CA, Abramson N, Johnston RB, et al. Increased susceptibility to infection associated with abnormalities of complement mediated functions and of the third component of complement (C3). N Engl J Med 1970, 282:350-354.
23. Zheng XL, Sadler JE Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008, 3:249-277.
24. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16:555-563.
25. Brady HR, Wilcox CS Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's The Kidney 2008, Saunders Elsevier, Philadelphia. 3rd ed.
26. Weiner CP Thrombotic microangiopathy in pregnancy and the postpartum period. Semin Hematol 1987, 24:119-129.
27. Martin JN, Bailey AP, Rehberg JF, et al. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006. Am J Obstet Gynecol 2008, 199:98-104.
28. Katz L, de Amorim MM, Figueiroa JN, et al. Postpartum dexamethasone for women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: A double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 2008, 198:1-8.
29. Ruggenenti P, Galli M, Remuzzi G Hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, and antiphospholipid antibody syndromes. Immunologic Renal Diseases 2001, 1179-1208. Lippincott Williams & Wilkins, Philadelphia. 2nd ed. E.G. Neilson, W.G. Couser (Eds.).
30. Adamson R, Sangle S, Kaul A, et al. Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin Rheumatol 2008, 14:359-360.
31. Thompson CE, Damon LE, Ries CA, et al. Thrombotic microangiopathies in the 1980s: Clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992, 80:1890-1895.
32. Pisoni R, Ruggenenti P, Remuzzi G Drug-induced thrombotic microangiopathy: Incidence, prevention and management. Drug Saf 2001, 24:491-501.
33. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000, 342:1773-1777.
34. Kojouri K, Vesely SK, George JN Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Frequency, clinical features, and long-term outcomes. Ann Intern Med 2001, 135:1047-1051.
35. Ruggenenti P Post-transplant hemolytic-uremic syndrome. Kidney Int 2002, 62:1093-1104.
36. Saland JM, Ruggenenti P, Remuzzi G Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009, 20:940-949.
37. Saland JM, Emre SH, Shneider BL, et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with factor H mutation. Am J Transplant 2006, 6:1948-1952.
38. Davin JC, Strain L, Goodship TH Plasma therapy in atypical haemolytic uremic syndrome: Lessons from a family with a factor H mutation. Pediatr Nephrol 2008, 23:1517-1521.
39. Gruppo RA, Rother RP Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009, 360:544-546.
40. Nuernberger J, Witzke O, Saez AO, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009, 360:542-544.